Jardine Matheson acquires I-MED Radiology for $2.4B

🔑 Enhanced Key Takeaways

•Jardine Matheson's acquisition of I-MED Radiology represents a significant strategic diversification into the healthcare sector, moving beyond its traditional focus on property, retail, and hospitality businesses.
•I-MED Radiology is Australasia's largest diagnostic imaging network, performing over 7 million patient procedures annually across its 215 clinics, and previously underwent ownership by private equity firms Permira (since 2018) and EQT (since 2014).
•Harrison.ai, the AI radiology specialist included in the acquisition, has raised over US$240 million in total capital across multiple funding rounds, including a US$112 million Series C in February 2025, and has secured 12 U.S. FDA clearances for its AI solutions.
•Harrison.ai's AI technology, including its Annalise Enterprise CXR and CT Brain solutions, is designed to analyze CT scans, X-rays, and pathology slides, assisting clinicians in detecting up to 130 findings on non-contrast head CTs and 124 findings on chest X-rays, with reported improvements in diagnostic accuracy and faster turnaround times.
•The acquisition values I-MED at approximately 11.5 times its forecast adjusted EBITDA for the 12 months ending June 2026 for its core business, excluding the Harrison.ai stake, and is expected to be earnings per share neutral in its first full year post-completion before becoming accretive.

🛠️ Technical Deep Dive

Harrison.ai's AI technology analyzes CT scans, X-rays, and pathology slides to assist clinicians in diagnosis.
Key radiology solutions include Annalise Enterprise CXR, which identifies up to 124 findings on X-rays, and a CT Brain solution (CTB) that detects up to 130 findings on non-contrast head CTs in under 90 seconds.
Harrison.ai has developed Harrison.rad.1, a radiology-specific generative AI model with emergent capabilities such as finding detection, localization, multi-modalities, structured reporting, open-ended chat, and clinical history understanding. This model reportedly outperforms other frontier models in the FRCR 2B Rapids exam.
The AI models are trained on proprietary, extensive, and diverse medical imaging datasets, with data annotated at scale by medical specialists to ensure high-quality training signals and clinical relevance.
The development process emphasizes robust validation, with studies grounded on gold-standard multi-reader, multi-case validation studies published in peer-reviewed journals, and each study hand-annotated by at least three independent, fully qualified radiologists.
Harrison.ai's solutions integrate seamlessly with existing clinical workflows, such as PACS and RIS, displaying findings in a resizable, no-click overlay window.
Features include customizable thresholds for individual findings (to optimize sensitivity/specificity), intelligent worklist prioritization to flag urgent cases, and explainable AI features like localization overlays and confidence bars.
The company has secured 12 U.S. Food and Drug Administration (FDA) clearances and received FDA breakthrough device designation and Medicare reimbursement for one of its CT brain algorithms.
In November 2025, Harrison.ai launched its Open Platform, offering an open architecture for radiologists and healthcare facilities to access a variety of AI applications with a single integration, aiming to eliminate traditional platform fees.

🔮 Future ImplicationsAI analysis grounded in cited sources

Jardine Matheson will significantly expand its presence in the Asia-Pacific healthcare diagnostics market and potentially into new international markets.

The acquisition aligns with Jardine's long-term strategy of owning market-leading businesses with growth potential in Asia-Pacific, and the company explicitly stated plans to support I-MED's expansion in core and new markets.

The integration of Harrison.ai's AI solutions within I-MED's extensive network will accelerate the adoption and impact of AI in diagnostic imaging across Australasia and potentially globally.

I-MED is the largest diagnostic imaging provider in the region, and Harrison.ai's technology is already integrated, suggesting a strong platform for scaling AI-powered diagnostics, improving efficiency and accuracy.

The deal will likely lead to increased investment in teleradiology capabilities and further development of AI-enabled diagnostic tools within the I-MED network.

Jardine Matheson plans to back I-MED's management to build out teleradiology and technology capabilities, and I-MED has already expanded its teleradiology services, including into the US.

⏳ Timeline

2000

I-MED Radiology Network founded in Sydney, Australia.

2014-04

EQT Mid Market acquired I-MED Radiology Network.

2018-01-27

Permira funds acquired I-MED Radiology Network from EQT.

2018

Harrison.ai founded.

2020

Harrison.ai partnered with I-MED Radiology to create the Annalise.AI solution.

2025-02-11

Harrison.ai secured US$112 million in Series C funding and announced expansion into the United States.

Jardine Matheson acquires I-MED Radiology for $2.4B

⚡ 30-Second TL;DR

Key Points

🧠 Deep Insight

🔑 Enhanced Key Takeaways

🛠️ Technical Deep Dive

🔮 Future ImplicationsAI analysis grounded in cited sources

⏳ Timeline

📎 Sources (22)

👉Related Updates